Oncology
No one ever wants to hear that their child has cancer. But if it happens, you do want to hear that you have one of the leading-edge children's cancer centers nearby–Cook Children's.
Cancer in children, teens and young adults is rare, and some types of childhood cancers are extremely rare. Finding an experienced team that has treated those cancers is literally a life-altering decision.
Cook Children's Oncology Program
The oncology program at Cook Children's is one of only a handful of pediatric cancer programs in the southwest, and one of only four in Texas that are a Children's Oncology Group member institute. In addition, our team of physician-researchers is among the most respected in the country. What that means to you and your child is access to tomorrow's treatments and cures, today.
Our doctors are actively pursuing cures for cancer. Because of our participation in ongoing national research studies, we are able to offer many patients the opportunity to participate in studies, giving them access to the most recent medicines and advanced treatments, including genetics, nuclear medicine, stem cell transplants, and more.
Our cancer center includes stem cell transplant rooms, an inpatient and outpatient infusion center, 28 inpatient beds in private rooms, a dedicated pharmacy, Texas' first and only I-131-MIBG suite for advanced targeted treatment of neuroblastoma tumors.
While our specialty is treating and curing cancer in our patients, we also take extra care of their childhood and teen years so that they can have the support and do not pause their lives as they grow into happy, healthy adults.
Who we treat
The oncology program at Cook Children's is open to any child from infancy through young adulthood who is suspected of having cancer, has been diagnosed with cancer, or who wants a second opinion. Our patients range in age from newborn to early 20s, and sometimes even older if we are one of the only centers close by that treats the type of cancer they have. We see patients from our local area and those in other states in even other countries. And thanks to the support of our community and our social services team, we never turn away a child who needs care simply because they can't afford it.
What we treat
The oncology team at Cook Children's treats all types of cancers and tumors in children, including:
Our specialty care team
-
Additional team members
-
Lisa Bashore
PhD, RN, CPNP, CPON -
Amy Bayles
MSN, RN, CPNP, CPON -
Lisa Dalton
MSN, RN, FNP-BC
Active oncology research studies
-
A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-024 (OPEN)
-
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) - ACNS1821
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-054 (OPEN)
-
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-006 (TEMPORARILY CLOSED TO ACCRUAL)
-
A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Primary Investigator: Granger MD, Meaghan
IRB ID: 2021-086 (TEMPORARILY CLOSED TO ACCRUAL)
-
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Primary Investigator: Heym MD, Kenneth
IRB ID: 2017-049 (OPEN)
-
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2021-071 (OPEN)
-
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Primary Investigator: Albritton MD, Karen
IRB ID: 2022-122 (OPEN)
-
A Phase 3 Randomized Study of Selumetinib (IND #77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG))
Primary Investigator: Murray MD, Jeffrey
IRB ID: 2019-075 (OPEN)
-
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-072 (TEMPORARILY CLOSED TO ACCRUAL)
-
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-022 (OPEN)
-
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-019 (OPEN)
-
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations - ACNS1931
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2021-017 (OPEN)
-
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Primary Investigator: Heym MD, Kenneth
IRB ID: 2019-059 (OPEN)
-
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Primary Investigator: Heym MD, Kenneth
IRB ID: 2023-008 (OPEN)
-
A Randomised Phase 3 trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Primary Investigator: Vallance MD, Kelly
IRB ID: 2018-089 (OPEN)
-
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2021-083 (OPEN)
-
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Primary Investigator: Albritton MD, Karen
IRB ID: COG_ACCL1931_Albritton (TEMPORARILY CLOSED TO ACCRUAL)
-
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-016 (OPEN)
-
A RETROSPECTIVE STUDY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKEMIA
Primary Investigator: Pacenta, Holly
IRB ID: 2023-062 (OPEN)
-
ALTE22C1: Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)
Primary Investigator: Beam MD, Donald
IRB ID: 2024-009 (OPEN)
-
AML23: A phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia
Primary Investigator: Heym MD, Kenneth
IRB ID: St. Jude_AML23_Heym (OPEN)
-
APAl2020SC
Primary Investigator: Vallance MD, Kelly
IRB ID: 2024-008 (OPEN)
-
ARAR2221 A Phase 2 Study Using Chemoimmunotherapy with Gemcitanine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinona (NPC) was activated today through COG
Primary Investigator: Greer MD, Chelsee
IRB ID: 2024-071 (OPEN)
-
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors. A COG Groupwide Observational Study.
Primary Investigator: Beam MD, Donald
IRB ID: COG_ALTE21C1_Beam (OPEN)
-
CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-066 (OPEN)
-
COG Study ALTE03N1: Key Adverse Events after Childhood Cancer
Primary Investigator: Granger MD, Meaghan
IRB ID: 543 (OPEN)
-
COG_AHOD2131_Albritton
Primary Investigator: Albritton MD, Karen
IRB ID: 2023-056 (OPEN)
-
Exploration of Perceived Stress, Sleep, Fatigue, and Biomarkers in Childhood Brain Tumor Survivors
Primary Investigator: Bashore NP, Lisa M
IRB ID: 2018-010 (OPEN)
-
Fort Worth AYA Oncology Coalition Registry Database
Primary Investigator: Albritton MD, Karen
IRB ID: 2019-017 (OPEN)
-
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Primary Investigator: Beam MD, Donald
IRB ID: 2014-023 (OPEN)
-
Kaposiform Hemangioendothelioma: Hematology and Oncology Survey (KHHAOS) Study
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-051 (OPEN)
-
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Primary Investigator: Beam MD, Donald
IRB ID: 2010-109 (OPEN)
-
National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Primary Investigator:
IRB ID: 2020-034 (OPEN)
-
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations (APEC1621F)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2018-003 (OPEN)
-
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (APEC1621SC)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2017-065 (OPEN)
-
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Primary Investigator: Akers DO, Lauren
IRB ID: 2018-066 (TEMPORARILY CLOSED TO ACCRUAL)
-
PEPN22P1: A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
Primary Investigator: Pacenta, Holly
IRB ID: 2022-112 (OPEN)
-
Randomization of Cytarabine Monotherapy versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis
Primary Investigator: Ray MD, Anish
IRB ID: 2019-067 (OPEN)
-
Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium Retrospective Chart Review
Primary Investigator: Heym MD, Kenneth
IRB ID: 2019-051 (OPEN)
-
SELCLAX
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-056 (OPEN)
-
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Primary Investigator: Zhao, MD, Sibo
IRB ID: St. Jude_SJiMB21_Zhao (OPEN)
-
Targeted approach to Langerhans Cell Histiocytosis (LCH) using MEK inhibitor, Trametinib.
Primary Investigator: Ray MD, Anish
IRB ID: CCMC_LCH Targeted therapy_Ray (OPEN)
-
Tissue Banking- Collecting and Banking Human Tissue Samples for Future Use
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2020-093 (OPEN)
-
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-097 (OPEN)
-
Venetoclax EAP IND 152442
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-080 (OPEN)
We are here to help.
If your child has been diagnosed, you probably have lots of questions. We can help. If you would like to schedule an appointment, refer a patient or speak to our staff, please call our offices at 682-885-6152.